Last Updated: 2026

Agios Pharmaceuticals

Rank#5170

Market Cap1.67B

CountryUnited States

Summary

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

History

Agios Pharmaceuticals was founded in 2007 and made its debut on the NASDAQ in July 2013. Its research and development program has advanced rapidly, and the company soon established itself as a leader in cancer metabolism and inborn errors of metabolism.

Mission

Agios’ mission is to make a transformative impact on patients’ lives through the discovery and development of innovative medicines addressing unmet medical needs.

Vision

Agios' vision is to become a premier, independent biopharmaceutical company focused on oncology and rare genetic metabolic diseases.

References

https://en.wikipedia.org/wiki/Agios_Pharmaceuticals

https://in.investing.com/equities/agios-pharm

https://finance.yahoo.com/quote/AGIO/profile?p=AGIO

https://www.crunchbase.com/organization/agios-pharmaceuticals

https://sec.report/CIK/0001439222

https://companiesmarketcap.com/

https://www.agios.com

Leadership team

Dr. Bruce D. Car DACVP, Ph.D. (Consultant)

Dr. Sarah Gheuens M.D., Ph.D. (Chief Medical Officer and Head of R&D)

Ms. Richa Poddar (Chief Commercial Officer)

Products / Services

Biotechnology, Health Care, Pharmaceutical

Number of Employees

100 - 500

Address

Cambridge, Massachusetts, United States

Established

2008-01-01

Company Registration

SEC CIK number: 0001439222

Revenue

5M - 20M

Traded as

AGIO

Website

https://www.agios.com

Social Media

Last Updated: 2026

Agios Pharmaceuticals

Rank#5170

Market Cap1.67B

CountryUnited States

Summary

History

Mission

Agios’ mission is to make a transformative impact on patients’ lives through the discovery and development of innovative medicines addressing unmet medical needs.

Vision

Agios' vision is to become a premier, independent biopharmaceutical company focused on oncology and rare genetic metabolic diseases.

References

https://en.wikipedia.org/wiki/Agios_Pharmaceuticals

https://in.investing.com/equities/agios-pharm

https://finance.yahoo.com/quote/AGIO/profile?p=AGIO

https://www.crunchbase.com/organization/agios-pharmaceuticals

https://sec.report/CIK/0001439222

https://companiesmarketcap.com/

https://www.agios.com

Leadership team

Dr. Bruce D. Car DACVP, Ph.D. (Consultant)